MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer

被引:180
作者
Lindegaard, Jacob C. [1 ]
Tanderup, Kari [2 ]
Nielsen, Soren Kynde [2 ]
Haack, Soren [3 ]
Gelineck, John [4 ]
机构
[1] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Med Phys, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Biomed Engn, DK-8000 Aarhus, Denmark
[4] Aarhus Univ Hosp, Dept Radiol, DK-8000 Aarhus, Denmark
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2008年 / 71卷 / 03期
关键词
pulsed-dose-rate brachytherapy; cervical cancer; image guided; treatment planning; magnetic resonance imaging; MRI;
D O I
10.1016/j.ijrobp.2007.10.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare dose-volume histogram parameters of standard Point A and magnetic resonance imaging-based three-dimensional optimized dose plans in 21 consecutive patients who underwent pulsed-dose-rate brachytherapy (PDR-BT) for locally advanced cervical cancer. Methods and Materials: All patients received external beam radiotherapy (elective target dose, 45 Gy in 25-30 fractions; tumor target dose, 50-60 Gy in 25-30 fractions). PDR-BT was applied with a tandem-ring applicator. Additional ring-guided titanium needles were used in 4 patients and a multichannel vaginal cylinder in 2 patients. Dose planning was done using 1.5 Tesla T-1-weighted and T-2-weighted paratransversal magnetic resonance imaging scans. T-1-weighted visible oil-containing tubes were used for applicator reconstruction. The prescribed standard dose for PDR-BT was 10 Gy (1 Gy/pulse, 1 pulse/h) for two to three fractions to reach a physical dose of 80 Gy to Point A. The total dose (external beam radiotherapy plus brachytherapy) was normalized to an equivalent dose in 2-Gy fractions using alpha/beta = 10 Gy for tumor, alpha/beta = 3 Gy for normal tissue, and a repair half-time of 1.5 h. The goal of optimization was dose received by 90% of the target volume (D-90) of >= 85 Gy(alpha/beta 10) in the high-risk clinical target volume (cervix and remaining tumor at brachytherapy), but keeping the minimal dose to 2 cm 3 of the bladder and rectum/sigmoid at < 90 and < 75 Gy(alpha/beta 3), respectively. Results: Using three-dimensional optimization, all dose-volume histogram constraints were met in 16 of 21 patients compared with 3 of 21 patients with two-dimensional library plans (p < 0.001). Optimization increased the minimal target dose (D-100) of the high-risk clinical target volume (p < 0.007) and decreased the minimal dose to 2 cm(3) for the sigmoid significantly (p = 0.03). For the high-risk clinical target volume, D-90 was 91 +/- 8 Gy(alpha/beta 10) and D-100 was 76 +/- 5 Gy(alpha/beta 10)). The minimal dose to 2 cm(3) for the bladder, rectum, and sigmoid was 73 +/- 6, 67 +/- 6, and 69 +/- 6 Gy(alpha/beta 3), respectively. Conclusion: The results of our study have shown that magnetic resonance imaging-guided optimization of PDR-BT for locally advanced cervical cancer significantly improved the dose-volume histogram parameters. (c) 2008 Elsevier Inc.
引用
收藏
页码:756 / 764
页数:9
相关论文
共 31 条
[1]  
ALBOOZ H, 2006, EGYPT NATL CANC I, V18, P156
[2]   Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: Clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy [J].
Bentzen, SM ;
Ruifrok, ACC ;
Thames, HD .
RADIOTHERAPY AND ONCOLOGY, 1996, 38 (02) :89-101
[3]   Unique role of proximal rectal dose in late rectal complications for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy [J].
Cheng, JCH ;
Peng, LC ;
Chen, YH ;
Huang, DYC ;
Wu, JK ;
Jian, JJM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (04) :1010-1018
[4]  
Dimopoulos J, 2006, RADIOTHER ONCOL, V81, pS39
[5]   Systematic evaluation of MRI findings in different stages of treatment of cervical cancer:: Potential of MRI on delineation of target, pathoanatomic structures, and organs at risk [J].
Dimopoulos, JCA ;
Schard, G ;
Berger, D ;
Lang, S ;
Goldner, G ;
Helbich, T ;
Pötter, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (05) :1380-1388
[6]   The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:: Clinical feasibility and preliminary results [J].
Dimopoulos, Johannes C. A. ;
Kirisits, Christian ;
Petric, Primoz ;
Georg, Petra ;
Lang, Stefan ;
Berger, Daniel ;
Poetter, Richard .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01) :83-90
[7]   PROGNOSTIC FACTORS IN PATIENTS WITH CERVIX CANCER TREATED BY RADIATION-THERAPY - RESULTS OF A MULTIPLE-REGRESSION ANALYSIS [J].
FYLES, AW ;
PINTILIE, M ;
KIRKBRIDE, P ;
LEVIN, W ;
MANCHUL, LA ;
RAWLINGS, GA .
RADIOTHERAPY AND ONCOLOGY, 1995, 35 (02) :107-117
[8]  
Georg P, 2006, RADIOTHER ONCOL, V81, pS38
[9]   Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group* (I):: concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV [J].
Haie-Meder, C ;
Pötter, R ;
Van Limbergen, E ;
Briot, E ;
De Brabandere, M ;
Dimopoulos, J ;
Dumas, I ;
Hellebust, TP ;
Kirisits, C ;
Lang, SF ;
Muschitz, S ;
Nevinson, J ;
Nulens, A ;
Petrow, P ;
Wachter-Gerstner, N .
RADIOTHERAPY AND ONCOLOGY, 2005, 74 (03) :235-245
[10]   The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer:: Design, application, treatment planning, and dosimetric results [J].
Kirisits, C ;
Lang, S ;
Dimopoulos, J ;
Berger, D ;
Georg, D ;
Pötter, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (02) :624-630